IP Library Granted Patent US 12,414,849
Granted Patent B2
US 12,414,849 · App. 16/648,801 · Granted Sep 16, 2025

Implantable device

Inventors: Zhenjian Lin (Shenzhen, CN); Jun Hu (Shenzhen, CN); Hongtao Sun (Shenzhen, CN); Li Qin (Shenzhen, CN); Deyuan Zhang (Shenzhen, CN)
Assignee: BIOTYX MEDICAL (SHENZHEN) CO, LTD.
A61F2/04A61L31/10A61L31/14A61F2002/041A61F2002/047
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,414,849
App. No.
16/648,801
Granted
Sep 16, 2025
Kind
B2
Abstract

An implantable device including a matrix and a zinc-containing layer at least partially covering the substrate. The zinc-containing layer includes a zinc compound. The ratio of the mass of the zinc element in the zinc-containing layer to the surface area of the implantable device is 0.1-200 μg/mm2. The average porosity of the zinc-containing layer is 30% or less. By matching the ratio of the mass of zinc in the zinc-containing layer to the surface area of the implantable device with the average porosity of the zinc-containing layer, the release rate of zinc is controlled within a reasonable range so that the rate of formation of the zinc-containing substance is controlled such that the concentration of the zinc-containing substance accumulated in the tissue is higher than the concentration which inhibits the proliferation of smooth muscle cells, and is always lower than the toxic concentration which causes cell death.

Claims (46)

1. An implantable device, comprising:

a substrate and a zinc-containing layer at least partially covering the substrate, wherein the zinc-containing layer contains a zinc compound, wherein a ratio of a mass of zinc elements in the zinc-containing layer to a surface area of the substrate is 1 to 150 μg/mm 2 , and an average porosity of the zinc-containing layer is 1% to 15%;

wherein the zinc compound is selected from at least one of zinc gluconate, zinc tartrate, zinc lactate, zinc carbonate, zinc hydroxide, zinc sulfate, zinc chloride, zinc phosphate, zinc nitrate, zinc glycyrrhizinate, zinc citrate, zinc amino acid, zinc acetate, sodium zincate, and zinc sulfide;

wherein a content of zinc elements in the zinc-containing layer is 1.4 wt. % to 80 wt. %; and

wherein a thickness of the zinc-containing layer is 1 μm to 50 μm, wherein the substrate is made of a degradable material, a non-degradable material, or a partially degradable material: and wherein the implantable device is a vascular stent, a biliary stent, an esophageal stent, a urethral stent, an airway stent, or a vena cava filter.

2. The implantable device according to claim 1 , further comprising one or more additional zinc-containing layers; and wherein the zinc-containing layer further comprises a polymer.

3. The implantable device according to claim 2 , wherein the polymer is selected from at least one of a degradable polymer, a non-degradable polymer, or at least one of copolymers formed by at least one monomer forming the degradable polymer and at least one monomer forming the non-degradable polymer,

wherein the degradable polymer is selected from at least one of polylactic acid, polyglycolic acid, polycaprolactone, polyethylene succinate, polybutylene succinate and poly(β-hydroxybutyrate), and the non-degradable polymer is selected from at least one of polystyrene, polytetrafluoroethylene, polymethyl methacrylate, polycarbonate and polyethylene terephthalate;

wherein a weight average molecular weight of the polymer is 100,000 to 500,000.

4. The implantable device according to claim 1 , further comprising a barrier layer, wherein the barrier layer at least partially covers the zinc-containing layer.

5. The implantable device according to claim 4 , wherein the barrier layer further comprises a polymer;

wherein a sum of a thickness of the barrier layer and a thickness of the zinc-containing layer is greater than 0 μm and less than or equal to 50 μm.

6. The implantable device according to claim 5 , wherein the polymer is selected from at least one of a degradable polymer, a non-degradable polymer, or at least one of copolymers formed by at least one monomer forming the degradable polymer and at least one monomer forming the non-degradable polymer,

wherein the degradable polymer is selected from at least one of polylactic acid, polyglycolic acid, polycaprolactone, polyethylene succinate, polybutylene succinate and poly(β-hydroxybutyrate), and the non-degradable polymer is selected from at least one of polystyrene, polytetrafluoroethylene, polymethyl methacrylate, polycarbonate and polyethylene terephthalate;

wherein a weight average molecular weight of the polymer is 100,000 to 500,000.

7. An implantable device, comprising:

a substrate and a zinc-containing layer at least partially covering the substrate, wherein the zinc-containing layer contains a zinc compound, wherein a ratio of a mass of zinc elements in the zinc-containing layer to a surface area of the substrate is 1 to 150 μg/mm 2 ;

wherein the zinc compound is selected from at least one of zinc gluconate, zinc tartrate, zinc lactate, zinc carbonate, zinc hydroxide, zinc sulfate, zinc chloride, zinc phosphate, zinc nitrate, zinc glycyrrhizinate, zinc citrate, zinc amino acid, zinc acetate, sodium zincate, and zinc sulfide;

wherein an average porosity of the zinc-containing layer is 1% to 30%;

wherein a content of zinc elements in the zinc-containing layer is 1.4 wt. % to 80 wt. %; and

wherein a thickness of the zinc-containing layer is 1 μm to 50 μm , wherein the substrate is made of a degradable material, a non-degradable material, or a partially degradable material: and wherein the implantable device is a vascular stent, a biliary stent, an esophageal stent, a urethral stent, an airway stent, or a vena cava filter.

8. The implantable device according to claim 7 ,

wherein the implantable device further comprising one or more additional zinc-containing layers; and/or

wherein the zinc-containing layer further comprises a polymer.

9. The implantable device according to claim 8 , wherein the polymer is selected from at least one of a degradable polymer, a non-degradable polymer, or at least one of copolymers formed by at least one monomer forming the degradable polymer and at least one monomer forming the non-degradable polymer,

wherein the degradable polymer is selected from at least one of polylactic acid, polyglycolic acid, polycaprolactone, polyethylene succinate, polybutylene succinate and poly(β-hydroxybutyrate), and the non-degradable polymer is selected from at least one of polystyrene, polytetrafluoroethylene, polymethyl methacrylate, polycarbonate and polyethylene terephthalate; and

wherein a weight average molecular weight of the polymer is 100,000 to 500,000.

10. The implantable device according to claim 7 , further comprising a barrier layer, wherein the barrier layer at least partially covers the zinc-containing layer; and

wherein the porosity of the zinc-containing layer is 1% to 15%.

11. The implantable device according to claim 10 , wherein the barrier layer further comprises a polymer; and wherein a sum of a thickness of the barrier layer and a thickness of the zinc-containing layer is greater than 0 μm and less than or equal to 50 μm.

12. The implantable device according to claim 11 , wherein the polymer is selected from at least one of a degradable polymer, a non-degradable polymer, or at least one of copolymers formed by at least one monomer forming the degradable polymer and at least one monomer forming the non-degradable polymer,

wherein the degradable polymer is selected from at least one of polylactic acid, polyglycolic acid, polycaprolactone, polyethylene succinate, polybutylene succinate and poly(β-hydroxybutyrate), and the non-degradable polymer is selected from at least one of polystyrene, polytetrafluoroethylene, polymethyl methacrylate, polycarbonate and polyethylene terephthalate; and

wherein a weight average molecular weight of the polymer is 100,000 to 500,000.

13. An implantable device, comprising:

a substrate and a zinc-containing layer at least partially covering the substrate, wherein the zinc-containing layer contains a zinc compound, wherein a ratio of a mass of zinc elements in the zinc-containing layer to a surface area of the substrate is 0.1 to 200 μg/mm 2 ;

wherein the zinc compound is selected from at least one of zinc gluconate, zinc tartrate, zinc lactate, zinc carbonate, zinc hydroxide, zinc sulfate, zinc chloride, zinc phosphate, zinc nitrate, zinc glycyrrhizinate, zinc citrate, zinc amino acid, zinc acetate, sodium zincate, and zinc sulfide;

wherein the implantable device further comprises a barrier layer

wherein a sum of a thickness of the barrier layer and a thickness of the zinc-containing layer is greater than 0 μm and less than or equal to 50 μm; and

wherein a content of zinc elements in the zinc-containing layer is 1.4 wt. % to 80 wt. %, wherein the substrate is made of a degradable material, a non-degradable material, or a partially degradable material: and wherein the implantable device is a vascular stent, a biliary stent, an esophageal stent, a urethral stent, an airway stent, or a vena cava filter.

14. The implantable device according to claim 13 , an average porosity of the zinc-containing layer is 1% to 30%

wherein the barrier layer at least partially covers the zinc-containing layer; and/or

wherein the zinc-containing layer or the barrier layer further comprises a polymer.

15. The implantable device according to claim 14 , wherein the polymer is selected from at least one of a degradable polymer, a non-degradable polymer, or at least one of copolymers formed by at least one monomer forming the degradable polymer and at least one monomer forming the non-degradable polymer,

wherein the degradable polymer is selected from at least one of polylactic acid, polyglycolic acid, polycaprolactone, polyethylene succinate, polybutylene succinate and poly(β-hydroxybutyrate), and the non-degradable polymer is selected from at least one of polystyrene, polytetrafluoroethylene, polymethyl methacrylate, polycarbonate and polyethylene terephthalate; and

wherein a weight average molecular weight of the polymer is 100,000 to 500,000.

16. The implantable device according to claim 13 , further comprising one or more additional zinc-containing layers; wherein the ratio of the mass of zinc elements in the zinc-containing layer to the surface area of the substrate is 1 to 150 μg/mm 2 ; and wherein the porosity of the zinc-containing layer is 1% to 15%.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2021
From: LIFETECH SCIENTIFIC (SHENZHEN) CO., LTD
To: BIOTYX MEDICAL (SHENZHEN) CO., LTD.
Reel/Frame 055535/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2020
From: LIN, ZHENJIAN; HU, JUN; SUN, HONGTAO; QIN, LI; ZHANG, DEYUAN
To: LIFETECH SCIENTIFIC (SHENZHEN) CO., LTD
Reel/Frame 052190/0367 →
Priority Claims (1)
CN 201710922803.6 · Sep 30, 2017 · national
Continuity (1)
Related Publication 20200214822A1 · Jul 9, 2020
References Cited (26)
US 8277833B2 · Atanasoska et al. · 2012 [cited by applicant]
US 9265866B2 · Kramer-Brown · 2016 [cited by examiner]
US 20040111144A1 · Lawin · 2004 [cited by examiner]
US 20090324684A1 · Atanasoska et al. · 2009 [cited by applicant]
US 20120316633A1 · Flanagan · 2012 [cited by examiner]
US 20170106123A1 · Weber · 2017 [cited by examiner]
CA 2885981A1 · 2006 [cited by examiner]
CN 101180087A · 2008 [cited by applicant]
CN 101745147A · 2010 [cited by applicant]
CN 101874751B · 2013 [cited by applicant]
CN 103526261A · 2014 [cited by examiner]
CN 205964236U · 2017 [cited by applicant]
CN 106806938A · 2017 [cited by applicant]
CN 106902385A · 2017 [cited by applicant]
CN 106955374A · 2017 [cited by applicant]
EP 2425866A1 · 2012 [cited by applicant]
WO 2004037120A2 · 2004 [cited by applicant]
WO WO2009021209A2 · 2009 [cited by examiner]
Translation of description and also claims for CN 103526261 (Year: 2014). [cited by examiner]
McGuffie et al. Zinc oxide nanoparticle suspensions and layer-by-layer coatings inhibit staphylococcal growth, Jan. 2016, Nanomedicine: Nanotechnology, Biology and Medicine, V. 12, pp. 33-42. (Year: 2016). [cited by examiner]
Extended European Search Report issued on Jun. 9, 2021, including the Supplementary European Search Report and the European Search Opinion, in connection with corresponding EP Application No. 18861575.1 (8pp.). [cited by applicant]
Chinese Office Action issued on Feb. 24, 2021, in connection with corresponding CN Application No. 201710922803.6 (15pp., including machine-generated English translation). [cited by applicant]
Jun Ma, et al., “Bioabsorbable zinc ion induced biphasic cellular responses in vascular smooth muscle cells”, Scientific Reports, vol. 6, No. 1, Jul. 1, 2016, pp. 1-10 (10pp), at URL: https://www.nature.com/articles/sre… [cited by applicant]
Indian Office Action issued on May 29, 2021, in connection with corresponding IN Application No. 202017013817 (6pp). [cited by applicant]
International Search Report issued on Dec. 7, 2018 and Written Opinion in corresponding International application No. PCT/CN2018/106714; 9 pages. [cited by applicant]
Office Action issued on Aug. 31, 2022, in corresponding Chinese Application No. 201710922803.6, 15 pages. [cited by applicant]